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Abstract
Aims We aimed to assess whether expression of whole‐blood RNA of sodium proton exchanger 1 (NHE1) and glucose trans-
porter 1 (GLUT1) is associated with COVID‐19 infection and outcome in patients presenting to the emergency department with
respiratory infections. Furthermore, we investigated NHE1 and GLUT1 expression in the myocardium of deceased COVID‐19
patients.
Methods and results Whole‐blood quantitative assessment of NHE1 and GLUT1 RNA was performed using quantitative PCR
in patients with respiratory infection upon first contact in the emergency department and subsequently stratified by SARS‐
CoV‐2 infection status. Assessment of NHE1 and GLUT1 RNA using PCR was also performed in left ventricular myocardium
of deceased COVID‐19 patients.
NHE1 expression is up‐regulated in whole blood of patients with COVID‐19 compared with other respiratory infections at first
medical contact in the emergency department (control: 0.0021 ± 0.0002, COVID‐19: 0.0031 ± 0.0003, P = 0.01). The ratio of
GLUT1 to NHE1 is significantly decreased in the blood of COVID‐19 patients who are subsequently intubated and/or die (severe
disease) compared with patients with moderate disease (moderate disease: 0.497 ± 0.083 vs. severe disease: 0.294 ± 0.0336,
P = 0.036). This ratio is even further decreased in the myocardium of patients who deceased from COVID‐19 in comparison
with the myocardium of non‐infected donors.
Conclusions NHE1 and GLUT1 may be critically involved in the disease progression of SARS‐CoV‐2 infection. We show here
that SARS‐CoV‐2 infection critically disturbs ion channel expression in the heart. A decreased ratio of GLUT1/NHE1 could po-
tentially serve as a biomarker for disease severity in patients with COVID‐19.
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Introduction
In the current SARS‐CoV‐2 pandemic, markers of increased
risk for progression to severe disease are urgently needed
to allocate limited healthcare resources to patients who need
them most.
Furthermore, it is important to identify baseline medica-
tion that could be harmful (or beneficial) for patients with
SARS‐CoV‐2 infection. The ion transporter sodium proton
exchanger 1 (NHE1) is an important regulator of cellular pH
in many tissues and is involved in the cellular response to
stress, such as inflammation and infection.1,2 Additionally,
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the glucose transporter 1 (GLUT1) is a critical glucose trans-
porter in many tissues, especially the heart.3
It has previously been shown that inhibitors of sodium–
coglucose transporter 2 (SGLT2 inhibitors) may exert their
beneficial effects directly on the heart via inhibition of
NHE1,4,5 as SGLT2 is not present in the heart.6 Additionally,
our working group has shown recently in that gliflozins in-
crease myocardial expression of GLUT1, thus increasing glu-
cose uptake into cardiomyocytes7 while also altering
myocardial sodium homoeostasis.6 Furthermore, expression
and activity of NHE1 have been shown to be affected by hyp-
oxia and glucocorticoid levels, among others, via serum and
glucocorticoid‐inducible kinase 1 (Sgk1).8,9 It has been shown
that GLUT1 activity (but not expression) is also stimulated by
Sgk1.10 Also, regulation of cellular pH is dependent on both
GLUT1 expression and NHE1‐expression.11 Interestingly, in
the kidney, both low and high sodium levels can alter GLUT1
expression,12 and NHE1‐deficient mice show strongly in-
creased cardiac GLUT1 expression.13 As such, it is reasonable
that GLUT1 and NHE1 expression could be directly linked. We
aimed to assess if SARS‐CoV‐2 infection altered the expres-
sion profile of these important cellular transporters in the
blood of patients with COVID‐19. Furthermore, as COVID‐19
has been shown to affect cardiac function as well, we also in-
vestigated NHE1 and GLUT1 expression in the myocardium of
deceased COVID‐19 patients.
We present data from our ongoing prospective clinical ob-
servational study investigating COVID‐19 patients at initial
presentation to the emergency department (ED). We report
on whole‐blood quantitative assessment of NHE1 and GLUT1
RNA using quantitative PCR (qPCR).
Methods
Patients were included in the study if they presented with
signs of acute respiratory infection to the ED. Pre‐specified in-
clusion criteria were age ≥ 18 years and signs of acute respi-
ratory infection, possibly COVID‐19. As all SARS‐CoV‐2‐
positive patients reported symptomatic illness, the term
COVID‐19 is used synonymously for these patients. In this
study, we first included all patients with suspected
COVID‐19 (defined by respiratory tract infection ± reported
fever). Patients were then tested for SARS‐CoV‐2 infection.
The patients with negative SARS‐CoV‐2 test result, who pre-
sented themselves with viral or bacterial respiratory tract in-
fection, were used as control group.
Pre‐specified exclusion criteria were withdrawal of consent
or patients unable to consent and delay of life‐saving diag-
nostic or therapeutic procedures by inclusion into the study
(which did not occur in this study cohort). Researchers in-
volved in the qPCR analysis were blinded with respect to
group allocation/SARS‐CoV‐2 test status. As some patients
were referred to our hospital ED from general practitioners
with existing COVID‐19 diagnosis, nurses and physicians
drawing blood and taking clinical data could not always be
blinded to SARS‐CoV‐2 status, also for personnel safety con-
siderations. However, all patients included into the study
were treated equally with regard to diagnostic testing, timing
of the testing, and safety precautions. The current study was
approved by the Ethics Committee of the University of Re-
gensburg. Informed consent was obtained from all patients.
After consent, clinical baseline characteristics and vital
signs were documented for each patient. Furthermore, out-
come and complications during hospital stay were assessed.
Severe disease was defined as subsequent need for mechan-
ical ventilation, admission to an intensive care unit, or death.
Otherwise, patients were classified as moderate disease. An
overview of inclusion procedures and patient stratification
can be found in Figure 1.
For qPCR analysis, patient blood was drawn by
venepuncture from each consenting patient immediately
after admission to the ED and inactivated using Trifast
(Ambion, Waltham, MA, USA). RNA was extracted using
trichloromethane–chloroform solution and isopropanol solu-
tion. RNA was purified using the RNeasy Plus Mini Kit (Qiagen,
Venlo, Netherlands) and transcribed to cDNA. Quantitative
analysis of NHE1 and GLUT1 RNA was performed using
the respective primer (NHE1: Hs00300047_m1, GLUT1:
Hs00892681_m1, Applied Biosystems, Waltham, MA, USA)
on a TaqMan apparatus (Applied Biosystems), and expression
was normalized to β‐actin or GAPDH (β‐actin: Hs00357333_g1,
GAPDH: Hs02786624_g1, Applied Biosystems). An extended
description of the methodology can be found in the
Supporting Information. We chose whole‐blood analysis for
its easy applicability, requiring no separation stages of cells
or plasma, and for safety considerations, as SARS‐CoV‐2 can
easily be inactivated using Trifast without opening the blood
tubes, thus avoiding potentially hazardous aerosol generation.
To strengthen our RNA data from whole blood of patients
with COVID‐19, we also obtained left ventricular cardiac tis-
sue from patients who died of COVID‐19 and analysed
NHE1 and GLUT1 RNA in this cardiac tissue. Because of ethical
and legal concerns, these deceased patients were not all from
our ED study. However, infection had been verified by PCR
from respiratory material in all of these patients, and all pa-
tients had symptomatic illness, which was determined to be
the cause of death. As control tissue is extremely rare, we
used a combination of left ventricular tissues from patients
who had died from other respiratory infections or from pa-
tients whose hearts were destined for heart donations that
ultimately could not be performed. No clinical data are avail-
able regarding the control group. Of note, there was no dif-
ference between the entities comprising the control group.
As we had better experience with using GAPDH as a house-
keeper for NHE1 in cardiac tissue, we used this instead of
β‐actin for NHE1; however, to exclude this as confounder,
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we first analysed the ratio of GAPDH and β‐actin and found
no significant difference (data not shown).
For SARS‐CoV‐2 testing, our facility mainly tested throat
rinse water by PCR, but external test facilities also used
throat swabs and sputum, which was accepted for our study
if performed by a certified laboratory.
For statistical testing, normality was tested using the
Kolmogorov–Smirnov test. For data with normal distribution,
a Student’s t‐test was performed in case of two groups with-
out pairing. When testing multiple groups, an ANOVA was
performed. For data for which normality could not be as-
sumed, a Mann–Whitney U test was performed in case of
two groups without pairing. Otherwise, a Kruskal–Wallis test
was used. The respective post‐tests adjusting for multiple
testing are referenced in the figure legends. Categorical data
were tested using Fisher’s exact test. The significance level
was taken to 5% (two‐sided P). Data are presented as
mean ± SEM, if not otherwise indicated. No data were ex-
cluded from the analysis.
Statistics were performed using GraphPad Prism v8
(GraphPad Software, San Diego, CA, USA) and SPSS 26. Orig-
inal data can be made available in a blinded manner upon
reasonable request.
Results
For this study, 43 patients were included in our analysis of
whole‐blood RNA. In 21 of these patients (48.8%), SARS‐
CoV‐2 infection could be confirmed. Clinical characteristics
of these patients can be found in Table 1.
Patients in the study were mostly male, and the mean age
was 53.6 years, which was not significantly different between
patients with confirmed SARS‐CoV‐2 infection and control.
Body mass index was increased but similar in both groups.
The median time from symptom onset to presentation in
the ED differed significantly between the SARS‐CoV‐2 positive
Figure 1 Overview of trial design. Patients were included in the study if they presented with signs of acute respiratory infection to the emergency
department. Pre‐specified inclusion criteria were age ≥ 18 years and signs of acute respiratory infection. We included all patients with suspected
COVID‐19 (defined by respiratory tract infection ± reported fever). For quantitative PCR analysis, patient blood was drawn by venepuncture from each
consenting patient immediately after admission to the emergency department. Patients were then tested for SARS‐CoV‐2 infection. The patients with
negative SARS‐CoV‐2 test result, who presented themselves with viral or bacterial respiratory tract infection, were used as control group. After con-
sent, clinical baseline characteristics and vital signs were documented, and outcome and complications during hospital stay were assessed. Severe dis-
ease was defined as subsequent need for mechanical ventilation, admission to an intensive care unit, or death. Otherwise, (standard care) patients
were classified as moderate disease.
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cohort and the control group. Clinical symptoms, vital signs,
or National Early Warning Score‐2 (NEWS‐2) scoring on ad-
mission were not significantly different between both groups.
In venous blood gas testing, pH, standard base excess, stan-
dard bicarbonate, and pCO2 did not differ between SARS‐
CoV‐2 and control groups (Supporting Information, Table
S1). In a non‐parametric correlation analysis, there was no
significant association between NHE1 expression and pH in
the SARS‐CoV‐2 or the control group.
In the SARS‐CoV‐2 group, one patient (4.8%), compared to
six patients in the control group (27.3%), had diabetes
mellitus, which was numerically different but did not reach
statistical significance. Patients in the control group suffered
significantly more often from coronary artery disease. Re-
garding drug therapy, only the usage of statins differed signif-
icantly between both groups.
NHE1 expression from whole blood was significantly ele-
vated in patients with SARS‐CoV‐2 in comparison with control
(P = 0.01; Figure 2A). There was no difference between male
and female patients (P = not significant). RNA expression of
GLUT1 was not significantly different between control group
and COVID‐19 patients (Figure 2B).
The ratio of GLUT1 and NHE1 whole‐blood RNA expression
in SARS‐CoV‐2‐positive patients, however, was significantly
reduced compared with control (Figure 2C).
In a stepwise multivariate linear regression analysis, only
SARS‐CoV‐2 status was significantly associated with NHE1 ex-
pression (P = 0.015), in contrast to diabetes, gender, age, cor-
onary artery disease, heart failure, obesity, arterial
hypertension, hyperlipidaemia, smoking, and statin usage,
which were non‐significant covariates (each P = not
significant).
Table 1 Patient characteristics
Control (n = 22) SARS‐CoV‐2 (n = 21) Statistics
Baseline characteristics
Age 57.1 ± 4.1 49.9 ± 3.6 P = 0.2a
Sex, % male (n) 59.1 (13) 57.1 (12) P > 0.9b
BMI 26.9 ± 1.1 27.8 ± 1.2 P = 0.6a
Smokers (continued), % (n) 9.1 (2) 9.5 (2) P > 0.9b
Diabetes, % (n) 27.3 (6) 4.8 (1) P = 0.09b
Hypertension, % (n) 50 (11) 28.6 (6) P = 0.2b
Coronary artery disease, % (n) 40.9 (9) 4.8 (1) P = 0.009b
Chronic kidney disease, % (n) 13.6 (3) 9.5 (2) P > 0.9b
COPD, % (n) 18.2 (4) 0 (0) P = 0.1b
Asthma, % (n) 13.6 (3) 0 (0) P = 0.2b
Baseline medication
Baseline medication, % (n) 68.2 (15) 61.9 (13) P = 0.8b
ACE‐/AT1‐inhibitors, % (n) 40.9 (9) 19.1 (4) P = 0.2b
Beta‐blockers 27.3 (6) 19.1 (4) P = 0.7b
Aspirin (100 mg/day), % (n) 36.4 (8) 14.3 (3) P = 0.2b
Statins, % (n) 40.9 (9) 4.8 (1) P = 0.009b
Metformin, % (n) 13.6 (3) 0 (0) P = 0.2b
DPP4‐inhibitors, % (n) 9.1 (2) 0 (0) P = 0.5b
Sulfonylurea, % (n) 0 (0) 0 (0) P > 0.9b
Gliflozins, % (n) 0 (0) 0 (0) P > 0.9b
Incretins, % (n) 0 (0) 0 (0) P > 0.9b
Insulin, % (n) 4.6 (1) 4.8 (1) P > 0.9b
Immunosuppressants, % (n) 13.6 (3) 9.5 (2) P > 0.9b
Symptoms
Onset of symptoms to presentation (days), median (95% CI) 3.5 (1; 8) 8 (5; 13) P = 0.01c
Fatigue, % (n) 90.9 (20) 100 (22) P = 0.5b
Fever, % (n) 72.7 (16) 77.3 (17) P > 0.9b
Dyspnoea, % (n) 63.6 (14) 66.7 (14) P > 0.9b
Coughing, % (n) 68.2 (15) 71.4 (15) P > 0.9b
Chills, % (n) 59.1 (13) 61.9 (13) P > 0.9b
Physical markers
Body temperature (°C) 37.6 ± 0.2 37.7 ± 0.2 P = 0.8c
SpO2 (%) 95.3 ± 0.6 94.95 ± 0.8 P = 0.7
a
Respiratory rate (/min) 20.5 ± 1.3 22 ± 1.5 P = 0.4c
Heart rate (b.p.m.) 89.2 ± 4.5 95.6 ± 3.3 P = 0.3a
Systolic blood pressure (mmHg) 134.2 ± 5.2 132.9 ± 4.3 P = 0.95c
Diastolic blood pressure (mmHg) 83.0 ± 2.9 80.4 ± 2.9 P = 0.5a
NEWS‐2 score 3.1 ± 0.5 3.8 ± 0.6 P = 0.4c
ACE, angiotensin‐converting enzyme; AT1, angiotensin II‐receptor‐subtype 1; BMI, body mass index; CI, confidence interval; COPD,
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Five patients in the SARS‐CoV‐2 group had severe disease,
and three of these five patients died. Neither NHE1 expres-
sion nor GLUT1 expression differed significantly between
the COVID‐19 patients with moderate disease and the pa-
tients with severe disease (Figure 2D,E). The NEWS‐2 score
was not different at first medical contact in the ED between
COVID‐19 patients with moderate disease and patients with
severe disease (moderate disease: 3.4 ± 0.7, severe disease:
4.8 ± 1.4, P = 0.26). The ratio of GLUT1 and NHE1 expression
was significantly lower in patients with severe disease com-
pared with moderate disease (Figure 2F).
RNA expression of NHE1 and GLUT1 was assessed in left
ventricular myocardial tissue from patients who died of
COVID‐19 (n = 6) and the control cohort (n = 7). Limited clin-
ical data for the COVID‐19 patients are shown in Supporting
Information, Table S2. NHE1 expression was significantly ele-
vated in patients who died from COVID‐19 compared with
controls (Figure 3A). Furthermore, the expression of GLUT1
was significantly lower in the patients who had died from
COVID‐19 compared with controls (Figure 3B). The ratio of
GLUT1 to NHE1 was significantly lower in patients with
COVID‐19 than in the control group (Figure 3C).
Discussion
For the first time, the current study shows that NHE1 RNA ex-
pression is up‐regulated in the blood of patients with
COVID‐19 compared with other respiratory infections, which
can be determined already at first contact in the ED. Further-
more, the ratio of GLUT1 to NHE1 is significantly lower in the
blood of COVID‐19 patients who are subsequently intubated
and/or die compared with moderately ill patients. Interest-
ingly, this expression profile of NHE1 and GLUT1 extends be-
yond the blood, as expression of both transporters is
Figure 2 Sodium proton exchanger 1 (NHE1) and glucose transporter 1 (GLUT1) expression in the blood of COVID‐19 patients. (A) NHE1 expression is
significantly increased in whole blood of patients with SARS‐CoV‐2 infection (SARS‐CoV‐2 positive) at first contact in the emergency department com-
pared with control (CTRL; P = 0.01, Mann–Whitney U test). (B) GLUT1 expression is not significantly altered in whole blood of patients with SARS‐CoV‐2
infection compared with CTRL (P = 0.29, Mann–Whitney U test). (C) The ratio of GLUT1 and NHE1 is significantly decreased in patients with SARS‐CoV‐2
infection compared with CTRL (P = 0.0039, Mann–Whitney U test). (D and E) In patients with COVID‐19 at first contact in the emergency department,
(D) NHE1 or (E) GLUT1 expression is not significantly different in patients who later develop moderate disease (MD) compared with patients later re-
quiring intubation and/or dying [severe disease (SD); (D): P = 0.99, t‐test; (E): P = 0.30, t‐test]. (F) GLUT1 to NHE1 ratio is significantly decreased in
patients with SD compared with patients with MD (P = 0.036, Welsh t‐test).
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significantly altered in left ventricular myocardium of de-
ceased COVID‐19 patients. The ratio of GLUT1 and NHE1 in
the myocardium of deceased COVID‐19 patients was signifi-
cantly lower, resembling the lower ratio of GLUT1 and
NHE1 in the blood of COVID‐19 patients in the ED, who are
subsequently at risk of intubation or death. This suggests that
NHE1 and GLUT1may be critically involved in the disease pro-
gression of SARS‐CoV‐2 infection.
In COVID‐19, increased inflammatory markers such as
C‐reactive protein and interleukin 6 have been reported, es-
pecially in severe COVID‐19 cases.14 Cardiac complications,
such as myocarditis, arrhythmias, acute coronary syndrome,
or acute heart failure, are known complications in severe dis-
ease courses. Furthermore, elevated levels of cardiac
markers, like cardiac troponin or brain natriuretic peptide,
are common in these patients as surrogate of myocardial
damage due to inflammation or ischaemia.14,15 A potential
explanation of the increased cardiovascular morbidity in
COVID‐19 is the binding of SARS‐CoV‐2 to the host receptor
angiotensin‐converting enzyme 2, which is highly expressed
in the human heart and vascular cells, but exact pathophysi-
ological processes of myocardial damage are still not fully
understood.
NHE is an ion transporter protein family, which plays a crit-
ical role in regulation of intracellular pH or cell volume, and
NHE1 is the predominant isoform of the NHE family in myo-
cardial and vascular cells.16 Previous studies found an in-
creased activity of NHE1 associated with hypertrophy,
cardiac fibrosis, and heart failure.17,18 Therefore, NHE1 has
been identified as a potential target in therapy of heart
failure.19 Recently, SGLT2 inhibitors, which decrease NHE1 ac-
tivity, have been discussed as potential therapeutic agents in
heart failure.20,21 Interestingly, NHE1 activity seems to be in-
volved in inflammatory response and leucocyte function.22,23
In this study, we found elevated NHE1 expression in whole
blood of patients with COVID‐19 in comparison with other
bacterial or viral infections. This elevated expression was also
present in myocardial tissue of deceased patients with
COVID‐19. Of note, inflammatory parameters like interleukin
6, C‐reactive protein, or white blood cell count did not differ
significantly between both groups (Supporting Information,
Table S3). A potential confounder due to increased inflamma-
tory response in the SARS‐CoV‐2 group cannot be excluded
but seems therefore unlikely. Under the aspect of increased
cardiovascular complications due to COVID‐19, the elevated
expression of NHE1 could potentially be involved in patho-
physiological pathways of cardiovascular damage due to
COVID‐19. Increased NHE1 expression and/or activity could
also be involved in or be dependent on altered platelet func-
tion in COVID‐19,24 as NHE1 activation contributes to platelet
activation. Interestingly, platelet activation can also be modu-
lated by SGLT2 inhibitors.25 In our COVID‐19 cohort, the
platelet count is not significantly different between the con-
trol group and the COVID‐19 group (Supporting Information,
Table S3). COVID‐19 patients with moderate disease and se-
vere disease show no difference in platelet counts (moderate
disease: 195.2 ± 14.84 vs. severe disease: 144.6 ± 35.25, t‐test
P = 0.14, data expressed as mean ± SEM). Pearson correla-
tions for platelet counts and NHE1 expression in the blood
show neither a significant correlation in the control or
COVID‐19 group nor when looking at COVID‐19 patients with
moderate vs. severe disease. However, platelet count and
platelet activity may of course differ, but as we used lysed
whole blood for our experiments (safety for our personnel),
Figure 3 Sodium proton exchanger 1 (NHE1) and glucose transporter 1 (GLUT1) expression in left ventricular (LV) myocardium of deceased COVID‐19
patients. (A) In LV myocardium of deceased COVID‐19 patients (SARS‐CoV‐2 positive), NHE1 expression is significantly decreased compared with con-
trols (CTRL; P = 0.016, t‐test). (B) In LV myocardium of deceased COVID‐19 patients (SARS‐CoV‐2 positive), GLUT1 expression is significantly decreased
compared with CTRL (P = 0.004, t‐test). (C) Similar to the data from whole blood of patients in the emergency department, GLUT1/NHE1 ratio is sig-
nificantly decreased in LV myocardium of deceased COVID‐19 patients (SARS‐CoV‐2 positive), compared with CTRL (P = 0.018, t‐test).
6 J. Mustroph et al.
ESC Heart Failure ; :
DOI: 10.1002/ehf2.13063
we cannot determine platelet activity in our study cohort, as
this would require fresh samples with high safety precau-
tions. Nevertheless, after strong platelet activation, platelets
aggregate and thus cannot be measured in the bloodstream;
thus, platelet count is at least an indirect measure of platelet
activity.26
Interestingly, it has been shown that NHE1‐deficient mice
show strongly increased cardiac GLUT1 expression.13 GLUT1
is a glucose transporter of the GLUT family and ubiquitously
expressed in almost all tissues. Primary function of GLUT1 is
the basal cellular glucose uptake independent from insulin. In-
creased GLUT1 expression was shown in animal models of
myocardial ischaemia or system inflammatory response
syndrome,27,28 suggesting a compensatory mechanism due
to stress and hypoxia. While hypoxia can also increase NHE1
expression, among others, via Sgk1,8,9 activity of the kinase
has also been shown to alter GLUT1 activity. Further, GLUT1
expression was correlated with left ventricular contractility in
that system inflammatory response syndrome animal model.
Interestingly, a reduced myocardial GLUT1 expression was
found in patients with end‐stage heart failure in one study.29
In our study, GLUT1 whole‐blood RNA expression was not sig-
nificantly different between COVID‐19 patients or control, but
the ratio of GLUT1 to NHE1 was lower in patients with
COVID‐19 in comparison with control. In patients with severe
COVID‐19, the ratio was even lower than in patients with mod-
erate disease. These altered expressions on NHE1 and GLUT1
were similar in myocardial tissue of deceased patients with
COVID‐19. Furthermore, GLUT1 was significantly lower
expressed in the myocardial tissue of patients who deceased
due to COVID‐19. This pattern might reflect a maladaptation
to inflammatory stress and myocardial ischaemia in patients
with COVID‐19 and unfavourable disease progression. It may
also hint at disturbed cellular ion handling and pH regulation,
as both low and high sodium levels can alter GLUT1
expression,12 and regulation of cellular pH is dependent on
both GLUT1 expression and NHE1 expression and vice versa.11
Further research regarding the role of these transporters is
urgently warranted, especially regarding the potential effects
of gliflozins in COVID‐19, which have been reported to affect
both NHE1 and GLUT1.4,7
Potential limitations of our study include the low number
of diabetic patients in the COVID‐19 group, as diabetic pa-
tients are at increased risk of mortality when contracting
SARS‐CoV‐2. Also, we could not investigate the effects of
gliflozins on GLUT1 and NHE1 in COVID‐19 patients, which
will need to be addressed in the future. Furthermore, an ad-
ditional desirable control group for the analysis of cardiac ex-
pression of NHE1 and GLUT1 in deceased COVID‐19 patients
would arguably be tissue from patients who have recovered
from COVID‐19; however, this is of course not reasonably ob-
tainable. In addition, these findings from a limited number of
patients from only one site have to be validated in larger pa-
tient cohorts in the near future, also exploring whether re-
duced GLUT1/NHE1 ratio is an independent risk factor for
mortality in COVID‐19.
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